Waters Introduces Next-Generation Alliance iS HPLC System Aimed at Reducing Up to 40% of Common Lab Errors
20.3.2023 15:00:00 EET | Business Wire | Press release
PITTCON 2023 – Waters Corporation (NYSE:WAT) today introduced Alliance iS, the next-generation intelligent HPLC System, designed to reduce compliance risk by adding new levels of proactive error detection, troubleshooting and ease-of-use. When combined with Waters’ compliance-ready Empower Chromatography Software and eConnect™ HPLC Columns, the Alliance iS High Performance Liquid Chromatography (HPLC) System streamlines the task of making accurate and precise measurements by detecting and eliminating common errors by up to 40%.i In doing so, the Alliance iS HPLC System helps QC laboratories consistently meet quality, safety, compliance, and on-time product delivery goals.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230320005167/en/
The new Waters Alliance iS HPLC System is an intuitively simple, rugged, and reliable high performance liquid chromatograph designed specifically for the pharmaceutical quality control (QC) laboratory. The instrument makes QC laboratories more efficient by reducing common errors that cause up to 40% of failed sample sets and subsequent out-of-specification results, re-tests and investigations. (Photo: Business Wire)
“Today’s QC laboratories are very different than they were 50 years ago when Waters introduced its first commercial HPLC system helping ensure the tens of thousands of prescription drugs on the market are pure, safe, and will work as expected,” said Udit Batra, President & CEO, Waters Corporation. “Our conversations with hundreds of QC managers and bench analysts have yielded a deeper understanding of what they need today from a state-of-the-art HPLC system to help them perform at their best. The Waters Alliance iS HPLC System is ideally suited to address issues such as staff training, error-reduction, risk management, and compliance, helping bring significant productivity and quality improvements to high-volume QC laboratories.”
Based on broad and in-depth customer insights, the Alliance iS HPLC System is thoughtfully designed for the unique needs of the QC laboratory, bringing intuitive simplicity to routine measurements. With visual prompts and alerts delivered via an intuitive touchscreen interface, the system notifies the operator if an improper method is chosen for an application, when a sample vial is missing, when it’s time to refill a solvent bottle, or if it’s time for system maintenance. These are common conditions that when caught early enough, can eliminate system errors that would otherwise degrade the ability of scientists to get needed drugs to patients and ultimately cost a laboratory time and money.
The system also integrates with the cloud-native waters_connect™ System Monitoring Software enabling real-time monitoring of the Alliance iS HPLC System and any other chromatography instruments controlled by Empower Software. Laboratory managers can view the live status of their HPLC instrument fleet from anywhere and at any time to further improve equipment utilization and overall productivity.ii
Waters Alliance iS HPLC System feature highlights include:
- The very latest compliance-ready, industry-standard Empower Chromatography Software with full audit tracking capabilities.
- Advanced instrument touchscreen for guided system operation and maintenance.
- eConnect Column Tag Technology to link column information including injection counts via near-field communication (NFC) technology.
- Automated system diagnostic pre-checks to help meet error reduction key performance indicators (KPIs).
- Tool-free fittings to prevent leaks and provide better chromatography.
The Waters Alliance iS HPLC System will be available starting in May 2023.
Additional Resources
- Learn more about Waters Alliance iS HPLC System product features and benefits
- Download the Alliance iS HPLC System brochure
- Read the blog post Waters Pushes the Boundaries with Intuitive Simplicity
- Visit the Waters online press kit for Alliance iS and PittCon ’23 news
- Follow and connect with Waters via LinkedIn, Twitter, and Facebook
About Waters Corporation (www.waters.com)
Waters Corporation (NYSE:WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, and food sciences for more than 60 years. With more than 8,200 employees worldwide, Waters operates directly in more than 35 countries, including 14 manufacturing facilities, and with products available in more than 100 countries.
Waters, Alliance, eConnect, waters_connect, and Empower are trademarks of Waters Corporation.
i *Estimate based on Waters' market research in 2022 after surveying 56 global pharmaceutical company QC labs.
ii The waters_connect System Monitoring application is only available in Europe and North America at this time.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230320005167/en/
Contact information
Brian J. Murphy
PR Manager, Corporate Communications
Waters Corporation
brian_j_murphy@waters.com
+1 508-482-2614
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 20263.10.2026 17:50:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by prior treatment, were presented at the 2026 International Gynecologic Cancer Society (IGCS) Annual Global Meeting in Montréal, Canada. Among patients evaluable for efficacy, three-year overall survival was 48% (n=35), unchanged from the two-year estimate, suggesting durable clinical benefit in this population. Responses and long-term survival were observed in both platinum-sensitive and platinum-resistant or refractory disease. At the last follow-up, 25% of patients who received at least one dose of treatment (11 of 44) were alive
emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer2.10.2026 18:12:00 EEST | Press release
emnify, a global leader in IoT connectivity, today announced the appointments of Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001902751/en/ emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer The appointments follow the recent naming of Kenneth De Spiegeleire as Chief Executive Officer and Frank Stoecker as Executive Chairman of the Board. Together, these leadership changes strengthen emnify financial, operational, and commercial capabilities as the company enters its next phase of international growth. “We have proven momentum. Our ambition is to now turn it into global category leadership,” said Kenneth De Spiegeleire, CEO of emnify. “That requires sharper focus, disciplined execution, and the right capabilities in the right seats. Sacha brings financial lead
Tacton Appoints Former IFS Executive Merlin Knott as Chief Commercial Officer to Accelerate Global Growth and Scale Beyond CPQ2.10.2026 16:00:00 EEST | Press release
Tacton, a global leader in Configure, Price, Quote (CPQ) software and configuration solutions for manufacturers of complex products, today announced the appointment of Merlin Knott as Chief Commercial Officer (CCO). In this role, Knott will lead Tacton’s global commercial organization, including marketing, sales, and pre-sales, aligning the teams responsible for bringing Tacton’s solutions to market, and driving value to its customers and partners globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261002794882/en/ Merlin Knott, Chief Commercial Officer, Tacton Knott joins Tacton with decades of experience building and scaling commercial organizations across the enterprise software industry. Most recently, he held senior leadership roles at IFS, the world’s leading provider of Industrial AI software, where he led global partner and channel operations before becoming President of the company’s Enterprise Service Manageme
EDW Presents 2026 Data Quality Award to Repeat Winner Domivest2.10.2026 16:00:00 EEST | Press release
European DataWarehouse (EDW) presented its fifth annual Data Quality Award at the 2026 TSI Congress in Berlin. This year, EDW's Best Data Quality – Deal of the Year (2026) award was presented to Domivest B.V. for its transaction Domi 2023-1 B.V., recognising the firm's outstanding commitment to accurate, complete, and consistent reporting. The award is based on EDW's proprietary data quality scoring methodology, which evaluates transactions against thousands of validation rules and checks. Data quality excellence is not a one-off achievement. The fact that the same issuers continue to rank among the top performers year after year demonstrates that superior data quality is the result of sustained commitment, robust processes, and ongoing investment. "Receiving the Data Quality Award for a second time means a great deal to us. Transparent, accurate loan-level data is key to investor trust in our transactions, and we are grateful to European DataWarehouse for recognising the work our trea
ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases2.10.2026 15:00:00 EEST | Press release
ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robust nasal mucosal immune responses in healthy children aged 6 through 17 years (LINK). The study demonstrated that a single intranasal dose of BPZE1 induced nasal mucosal immune responses against all Bordetella pertussis antigens tested and was well tolerated, both when administered alone and when co-administered with a tetanus-diphtheria-acellular pertussis (Tdap) booster vaccine. The multi-center Phase 2b trial enrolled 366 participants across 16 sites in the United Kingdom, Australia, and Costa Rica and included participants
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom